Why Farbe Firma is the Top Manufacturer of Dexketoprofen Injection
- Maulik Sudani
- Jun 29
- 9 min read
Last Updated: June 29, 2026
TL;DR: Dexketoprofen Injection - a sterile, clear, colourless aqueous solution of dexketoprofen (as the trometamol salt), the active S(+)-enantiomer of ketoprofen and a potent propionic-acid (arylpropionic) NSAID, supplied commonly as a 50 mg/2 mL ampoule (25 mg/mL) given by intramuscular or slow intravenous injection - is the fast-acting, non-opioid analgesic clinicians use for the short-term management of acute moderate-to-severe pain such as post-operative pain, renal colic and acute musculoskeletal and low-back pain, where using only the active enantiomer delivers effective analgesia at roughly half the racemic dose. Because dexketoprofen is a single-enantiomer active that has to be held in solution as its highly soluble trometamol salt and kept free of its inactive R-enantiomer, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the enantiomeric (chiral) purity, the related-substance profile, the controlled pH, clarity, fill volume, low particulate and endotoxin, photostability, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Dexketoprofen Injection at our Gujarat, India facility and supplies it to surgical, anaesthesia, pain-management, emergency-medicine and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Propionic-acid (arylpropionic) NSAID and the active S(+)-enantiomer of ketoprofen - dexketoprofen inhibits cyclo-oxygenase to block prostaglandin synthesis and control pain, and Dexketoprofen Injection (50 mg/2 mL, as the trometamol salt, IM or slow IV) demands an exact, reproducible parenteral dose for the short-term management of acute moderate-to-severe pain.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule filling lines, control of the stability-indicating assay, the enantiomeric (chiral) purity, the related-substance profile, the controlled pH, clarity, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, chiral-purity and stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Dexketoprofen Injection Demands a Premium Manufacturer
Dexketoprofen Injection occupies a valuable place in modern acute-pain management across every market. It is the analgesic a clinician reaches for when a patient needs fast, strong, non-opioid relief from acute moderate-to-severe pain but cannot conveniently take a tablet - in the early hours after surgery, during an episode of renal colic, or in an acute flare of musculoskeletal or low-back pain. What makes dexketoprofen distinctive is that it is a single enantiomer: it is the S(+)-enantiomer of ketoprofen, the eutomer that carries essentially all of the cyclo-oxygenase-inhibitory analgesic activity, while the inactive R-enantiomer found in the older racemic product is removed. Isolating the active enantiomer allows effective analgesia at roughly half the milligram dose of racemic ketoprofen, and presenting it as the highly water-soluble trometamol salt supports a rapid onset of action. In a multimodal, opioid-sparing regimen, that combination of a fast onset and the lower effective dose of a single enantiomer is exactly why dexketoprofen has become a mainstay of injectable acute-pain control wherever a rapid, dependable non-opioid option is needed. Because the injection is given parenterally, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Dexketoprofen Injection is presented as a ready-to-use sterile solution - for example 50 mg of dexketoprofen (as the trometamol salt) in a 2 mL ampoule, 25 mg/mL, given by intramuscular or slow intravenous injection - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The defining challenge of a single-enantiomer active is chirality: the enantiomeric (chiral) purity of the product, that is its freedom from the inactive R-enantiomer, is a genuine critical quality attribute that has to be measured by a validated chiral HPLC method and held within tight limits, with no enantiomeric inversion or racemisation across shelf life. The active is solubilised and held in solution as its trometamol (tromethamine) salt at a controlled pH, so the solution stays clear, free of visible and sub-visible particulates and low in endotoxin, and the manufacturer must run a stability-indicating method that resolves and quantifies dexketoprofen and its related substances without interference. Dexketoprofen, like the other propionic-acid NSAIDs, is light-sensitive, so photostability under ICH Q1B and light-protective processing and packaging matter, and the right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated. The NSAID class cautions - the gastrointestinal, renal and cardiovascular thrombotic risks, and the risk of hypersensitivity and bronchospasm in susceptible patients - must be clearly carried on the label. Choosing a Dexketoprofen Injection manufacturer that treats the chiral purity, the stability-indicating assay, related-substance control, the controlled pH, photostability, and clarity and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Dexketoprofen Injection Manufacturer Apart
A world-class manufacturer of Dexketoprofen Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of dexketoprofen with enantiomeric (chiral) purity control and related-substance control by validated HPLC, which a single-enantiomer NSAID specifically demands; a robust, validated sterilisation and fill process built around a trometamol-solubilised solution that must stay clear and precipitate-free from compounding through to the point of use; and tender-ready dossier support, including chiral, photostability and accelerated stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial- or in-house-specification-grade dexketoprofen trometamol sourced from qualified, audited API makers, with full assay, enantiomeric-purity, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the regulatory dossier for an enantiopure drug stands or falls on demonstrated chiral purity, that single-enantiomer discipline is built in from the very first incoming-goods test rather than bolted on at release.
Compounding and filling then have to defend the assay, the clarity and, above all, the chiral purity of a single-enantiomer active. The bulk solution is compounded in water-for-injection with the trometamol salt at the controlled pH that holds dexketoprofen fully in solution, sterile-filtered through a 0.22 micron membrane and filled into ampoules - or vials - under ISO Class 5 conditions and under light protection, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of dexketoprofen by validated HPLC, the enantiomeric (chiral) purity by chiral HPLC, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular and intravenous administration. Because the active is a single enantiomer and light-sensitive, assay accuracy, chiral purity, related-substance control, pH control and photostability are confirmed together so the assay, the enantiomeric ratio and clarity stay within specification across shelf life, with no racemisation and no precipitation in the ampoule.
Quality Systems Behind Every Dexketoprofen Injection
Every Farbe Firma Dexketoprofen Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of dexketoprofen against reference standards, enantiomeric (chiral) purity by validated chiral HPLC, control of related substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, light-protected compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because dexketoprofen is a single-enantiomer, light-sensitive NSAID given parenterally and the assay, enantiomeric purity, related-substance profile and photostability drive both efficacy and safety, we treat the stability-indicating assay, the chiral purity, the related-substance profile and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with ICH Q1B photostability documented, so the assay, the enantiomeric ratio, clarity and colour stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Dexketoprofen Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anti-inflammatory and peri-operative small-volume parenteral portfolio. For Dexketoprofen Injection specifically, we supply the ready-to-use 50 mg/2 mL trometamol-salt solution in ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the chiral-purity, stability-indicating-assay, related-substance, pH, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification. Buyers can also request the supporting chiral-method-validation summary and representative photostability and accelerated-stability data up front, so technical evaluation and tender pre-qualification can proceed in parallel with commercial discussions.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, chiral-purity and stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including intramuscular and slow-intravenous administration instructions, store-below-25-degrees-C and protect-from-light storage directions, and the gastrointestinal, renal, cardiovascular and hypersensitivity-and-bronchospasm cautions of the NSAID class - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Dexketoprofen Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development and validation of a chiral HPLC method for an enantiopure NSAID, the stability-indicating assay, related-substance control, trometamol-salt solubility and formulation design, photostability strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a single-enantiomer NSAID where chiral purity and dose precision directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Dexketoprofen Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Dexketoprofen Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule filling lines, validated chiral-purity and stability-indicating analytics, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Dexketoprofen Injection do you supply?
Our standard presentation is the ready-to-use 50 mg/2 mL (25 mg/mL) solution of dexketoprofen, as the trometamol salt, in an ampoule for intramuscular or slow intravenous injection. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Dexketoprofen Injection mainly used for?
Dexketoprofen Injection is used for the short-term management of acute moderate-to-severe pain, such as post-operative pain, renal colic and acute musculoskeletal and low-back pain, when an oral dose is not practical. It is the active S(+)-enantiomer of ketoprofen, delivering effective analgesia at roughly half the racemic dose; Farbe Firma verifies the assay, the enantiomeric (chiral) purity, the related-substance profile, pH, clarity, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. It is given by intramuscular or slow intravenous injection, and the gastrointestinal, renal, cardiovascular and hypersensitivity cautions of the NSAID class are carried on the label.
Can Farbe Firma support country-specific registrations for Dexketoprofen Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, chiral-purity and stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Dexketoprofen Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our analgesia and anti-inflammatory small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments